CapsoVision, Inc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $13.6M | $11.8M | — |
| Cost of revenue | $6.4M | $5.4M | — |
| Gross profit | $7.2M | $6.4M | — |
| Research and development | $18.3M | $15.1M | — |
| Operating expenses | $32.7M | $26.3M | — |
| Operating income | -$25.5M | -$19.9M | — |
| Pretax income | -$25.3M | -$19.9M | — |
| Income tax expense | $24,000 | $11,000 | — |
| Net income | -$25.3M | -$19.9M | — |
| Balance Sheet | |||
| Current assets | $16.7M | $14.8M | — |
| Total assets | $18.2M | $16.8M | — |
| Current liabilities | $4.4M | $1.8M | — |
| Total liabilities | $4.9M | $2.7M | — |
| Stockholders' equity | $13.3M | -$129.5M | -$109.8M |
| Cash Flow Statement | |||
| Cash from operations | -$22.9M | -$20.1M | — |
| Depreciation and amortization | $216,000 | $206,000 | — |
| Stock-based compensation | $826,000 | $156,000 | — |
| Capital expenditure | $90,000 | $153,000 | — |
| Free cash flow | -$23.0M | -$20.2M | — |
| Impairments | $0 | $0 | — |
Shares outstanding 50.0M · Free float 67.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.